drugset
Drugs / MVF-HER-2(628-647)-CRL 1005 vaccine
last change Mar 2005 re-read 3 minutes ago

MVF-HER-2(628-647)-CRL 1005 vaccine

Vaccine

Developed for
breast cancer · gastric cancer · lung cancer · ovarian cancer
Investigated by
National Cancer Institute (NCI) · University of Alabama at Birmingham

Trials 1

today NCT00017537 · Ph 1
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00017537 Mar 2000 → Mar 2005 breast cancer, gastric cancer, lung cancer, ovarian cancer University of Alabama at Birmingham Withdrawn No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MVF-HER-2(628-647)-CRL 1005 vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00017537 ↗
Modality Vaccine “Active Specific Immunotherapy With MVF-HER-2(628-647) and CRL1005 Copolymer Adjuvant” NCT00017537 ↗
Route Intramuscular “Patients receive MVF-HER-2(628-647)-CRL 1005 vaccine intramuscularly on days 1 and 29.” NCT00017537 ↗